PE20191349A1 - Inhibidores de mnk sustituidos con piperidina y metodos relacionados con los mismos - Google Patents
Inhibidores de mnk sustituidos con piperidina y metodos relacionados con los mismosInfo
- Publication number
- PE20191349A1 PE20191349A1 PE2019001676A PE2019001676A PE20191349A1 PE 20191349 A1 PE20191349 A1 PE 20191349A1 PE 2019001676 A PE2019001676 A PE 2019001676A PE 2019001676 A PE2019001676 A PE 2019001676A PE 20191349 A1 PE20191349 A1 PE 20191349A1
- Authority
- PE
- Peru
- Prior art keywords
- piperidine
- amino
- alkyl
- related methods
- compounds
- Prior art date
Links
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical group C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title 2
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- -1 AMINO Chemical class 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
- XVIAPHVAGFEFFN-UHFFFAOYSA-N pyrimidine-5-carbonitrile Chemical compound N#CC1=CN=CN=C1 XVIAPHVAGFEFFN-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Abstract
SE REFIERE A COMPUESTOS SUSTITUIDOS CON PIPERIDINA DE FORMULA (I) DONDE X1 ES CH2 Y X2 ES NR2 O X1 ES NR2 Y X2 ES CH2; R1 ES H, ALQUILO(C1-C4), HALOGENO O CN; R2 ES H, ALQUILO(C1-C8) O HALOALQUILO(C1-C8); R3 ES ALQUILO(C1-C8), O R2 Y UN ADYACENTE R3, O R3 Y UN ADYACENTE R3, JUNTO CON LOS ATOMOS DEL ANILLO AL QUE ESTAN UNIDOS, FORMAN UN ANILLO DE CICLOALQUILO O HETEROCICLO FUSIONADO DE CINCO O SEIS MIEMBROS; n ES DE 0 A 4. SON COMPUESTOS PREFERIDOS: (R)-6-((6-AMINO-5-METILPIRIMIDIN-4-IL)AMINO)-1',8-DIMETIL-2H-ESPIRO[IMIDAZO[1,5-a]PIRIDINA-3,3'-PIPERIDINA]-1,5-DIONA; (R)-4-AMINO-6-((1',8-DIMETIL-1,5-DIOXO-1,5-DIHIDRO-2H-ESPIRO[IMIDAZO[1,5-a]PIRIDINA-3,3'-PIPERIDIN]-6-IL)AMINO)PIRIMIDINA-5-CARBONITRILO; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE QUINASA QUE INTERACTUAN CON MAP QUINASA (MnK) SIENDO UTILES EN EL TRATAMIENTO DE CANCER
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762458671P | 2017-02-14 | 2017-02-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20191349A1 true PE20191349A1 (es) | 2019-09-30 |
Family
ID=63106539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2019001676A PE20191349A1 (es) | 2017-02-14 | 2018-02-13 | Inhibidores de mnk sustituidos con piperidina y metodos relacionados con los mismos |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US20180228803A1 (es) |
| EP (1) | EP3582776B1 (es) |
| JP (2) | JP2020507588A (es) |
| KR (1) | KR20190117013A (es) |
| CN (1) | CN110719781A (es) |
| AU (2) | AU2018220840A1 (es) |
| BR (1) | BR112019016707A2 (es) |
| CA (1) | CA3053493A1 (es) |
| CL (1) | CL2019002297A1 (es) |
| CO (1) | CO2019009423A2 (es) |
| DK (1) | DK3582776T3 (es) |
| EA (1) | EA201991894A1 (es) |
| FI (1) | FI3582776T3 (es) |
| IL (1) | IL268619B (es) |
| MX (1) | MX2019009653A (es) |
| PE (1) | PE20191349A1 (es) |
| PH (1) | PH12019550140A1 (es) |
| SG (1) | SG11201907356SA (es) |
| TW (1) | TWI762579B (es) |
| WO (1) | WO2018152117A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2019009653A (es) | 2017-02-14 | 2019-12-19 | Effector Therapeutics Inc | Inhibidores de mnk sustituidos con piperidina y metodos relacionados con los mismos. |
| AU2019366947A1 (en) | 2018-10-24 | 2021-06-03 | Effector Therapeutics, Inc. | Crystalline forms of Mnk inhibitors |
| CN111484494B (zh) * | 2019-01-29 | 2022-09-13 | 诺沃斯达药业(上海)有限公司 | 抑制mnk1和mnk2的多环化合物 |
| JP7311207B2 (ja) | 2019-11-18 | 2023-07-19 | 成都嘉葆薬銀医薬科技有限公司 | Ｍｎｋ阻害剤としてのピロロトリアジン系化合物 |
| US20240092799A1 (en) * | 2020-08-20 | 2024-03-21 | Hepagene Therapeutics (HK) Limited | Mnk inhibitors |
| CN117355528A (zh) * | 2021-05-08 | 2024-01-05 | 成都嘉葆药银医药科技有限公司 | 吡咯并三嗪类化合物的盐型、其晶型及其制备方法 |
| CN114736205B (zh) * | 2022-03-31 | 2023-03-03 | 武汉九州钰民医药科技有限公司 | 化合物Tomivosertib的制备方法 |
| CN114853756B (zh) * | 2022-03-31 | 2023-03-28 | 武汉九州钰民医药科技有限公司 | 化合物Tomivosertib的制备工艺 |
| WO2024017229A1 (zh) * | 2022-07-19 | 2024-01-25 | 成都嘉葆药银医药科技有限公司 | 一种吡咯并三嗪类化合物在制备抗肿瘤药物中的应用 |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5491144A (en) | 1991-05-30 | 1996-02-13 | Ciba-Geigy Corporation | Substituted diaminophthalimides and analogues |
| MXPA03011080A (es) | 2001-06-05 | 2004-07-08 | Lilly Icos Llc | Compuestos tetraciclicos como inhibidores de pde5. |
| ES2359233T3 (es) | 2001-10-29 | 2011-05-19 | Boehringer Ingelheim International Gmbh | Proteínas homólogas de la quinasa mnk implicadas en la regulación de la homeostasis energética y en el metabolismo organular. |
| US20050012622A1 (en) | 2003-05-19 | 2005-01-20 | Sutton William R. | Monitoring and control of sleep cycles |
| TWI301760B (en) | 2004-02-27 | 2008-10-11 | Merz Pharma Gmbh & Co Kgaa | Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors |
| US7488745B2 (en) | 2004-07-16 | 2009-02-10 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
| TW200613272A (en) | 2004-08-13 | 2006-05-01 | Astrazeneca Ab | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators |
| US20060281670A1 (en) | 2005-06-10 | 2006-12-14 | Wisconsin Alumni Research Foundation (Warf) | Compositions and methods for modulating angiogenesis |
| CN101309905A (zh) | 2005-08-12 | 2008-11-19 | 阿斯利康(瑞典)有限公司 | 取代的异吲哚酮及其作为代谢型谷氨酸受体增效剂的用途 |
| CN101472912A (zh) | 2006-06-22 | 2009-07-01 | 比奥维特罗姆上市公司 | 作为mnk激酶抑制剂的吡啶和吡嗪衍生物 |
| EP1889847A1 (en) | 2006-07-10 | 2008-02-20 | DeveloGen Aktiengesellschaft | Pyrrolopyrimidines for pharmaceutical compositions |
| ES2485040T3 (es) | 2007-03-16 | 2014-08-12 | The Scripps Research Institute | Inhibidores de cinasa de adhesión focal |
| GB0706072D0 (en) | 2007-03-28 | 2007-05-09 | Sterix Ltd | Compound |
| WO2009065596A2 (en) | 2007-11-22 | 2009-05-28 | Develogen Aktiengesellschaft | Use of mnk inhibitors for the treatment of alzheimer's disease |
| JP2009173629A (ja) | 2007-12-21 | 2009-08-06 | Banyu Pharmaceut Co Ltd | Ｒｓｋ１阻害作用を有する新規スピロインダン誘導体 |
| WO2009112445A1 (en) | 2008-03-10 | 2009-09-17 | Novartis Ag | Method of increasing cellular phosphatidyl choline by dgat1 inhibition |
| US8486953B2 (en) | 2008-08-26 | 2013-07-16 | Boehringer Ingelheim International Gmbh | Thienopyrimidines for pharmaceutical compositions |
| US20110280886A1 (en) | 2008-11-12 | 2011-11-17 | University Hospital Basel | Treating cancer by modulating mnk |
| TWI468402B (zh) | 2009-07-31 | 2015-01-11 | 必治妥美雅史谷比公司 | 降低β－類澱粉生成之化合物 |
| US8637525B2 (en) | 2009-07-31 | 2014-01-28 | Bristol-Myers Squibb Company | Compounds for the reduction of beta-amyloid production |
| TWI393716B (zh) | 2009-08-04 | 2013-04-21 | Merck Sharp & Dohme | 作為ｉｘａ因子抑制劑之雜環化合物 |
| US8604217B2 (en) | 2009-11-12 | 2013-12-10 | Selvita S.A. | Compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent |
| WO2011106168A1 (en) | 2010-02-24 | 2011-09-01 | Dcam Pharma Inc | Purine compounds for treating autoimmune and demyelinating diseases |
| AP2013006834A0 (en) | 2010-10-01 | 2013-04-30 | Bayer Ip Gmbh | Substituted N-(2-arylamino)aryl sulfonamide-containing combinations |
| PT3042910T (pt) | 2010-11-30 | 2019-04-16 | Gilead Pharmasset Llc | 2'-espiro-nucleósidos para utilização na terapia da hepatite c |
| US9938269B2 (en) | 2011-06-30 | 2018-04-10 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
| WO2013043192A1 (en) | 2011-09-23 | 2013-03-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Galactokinase inhibitors for the treatment and prevention of associated diseases and disorders |
| RU2705577C2 (ru) | 2011-12-30 | 2019-11-08 | Ханми Фарм. Ко., Лтд. | ПРОИЗВОДНЫЕ ТИЕНО[3,2-d]ПИРИМИДИНА, ОБЛАДАЮЩИЕ ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ ПРОТЕИНКИНАЗ |
| EP3216792B1 (en) | 2012-03-29 | 2020-05-27 | G1 Therapeutics, Inc. | Lactam kinase inhibitors |
| US10280168B2 (en) | 2012-03-30 | 2019-05-07 | Agency For Science, Technology And Research | Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof |
| GB201205669D0 (en) | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
| WO2013151975A1 (en) | 2012-04-02 | 2013-10-10 | Northeastern University | Compositions and methods for the inhibition of methyltransferases |
| CN104470926A (zh) | 2012-05-21 | 2015-03-25 | 拜耳医药股份有限公司 | 取代的吡咯并嘧啶 |
| TW201412740A (zh) | 2012-09-20 | 2014-04-01 | Bayer Pharma AG | 經取代之吡咯并嘧啶胺基苯并噻唑酮 |
| ES2635262T3 (es) | 2012-11-09 | 2017-10-03 | Evotec International Gmbh | Quinazolinas sustituidas con sulfoximina para composiciones farmacéuticas |
| GB2508652A (en) | 2012-12-07 | 2014-06-11 | Agency Science Tech & Res | Heterocyclic piperazine derivatives |
| EP2935304A1 (en) | 2012-12-19 | 2015-10-28 | IDENIX Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
| US20160287589A1 (en) | 2013-02-20 | 2016-10-06 | Bayer Pharma Aktiengesellschaft | Substituted-imidazopyridazines |
| TW201605867A (zh) | 2013-11-20 | 2016-02-16 | 拜耳製藥公司 | 噻吩并嘧啶 |
| TWI713455B (zh) | 2014-06-25 | 2020-12-21 | 美商伊凡克特治療公司 | ＭｎＫ抑制劑及其相關方法 |
| TN2017000258A1 (en) | 2014-12-19 | 2018-10-19 | Bayer Pharma AG | Pyrazolopyridinamines as mknk1 and mknk2 inhibitors |
| WO2016172010A1 (en) * | 2015-04-20 | 2016-10-27 | Effector Therapeutics, Inc. | Inhibitors of immune checkpoint modulators for use in treating cancer and infections |
| KR20180070695A (ko) | 2015-10-29 | 2018-06-26 | 이펙터 테라퓨틱스, 인크. | Mnk1 및 mnk2의 이소인돌린, 아자이소인돌린, 디히드로인데논 및 디히드로아자인데논 억제제 |
| US20170121339A1 (en) | 2015-10-29 | 2017-05-04 | Effector Therapeutics, Inc. | Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds that inhibit mnk1 and mnk2 |
| WO2017087808A1 (en) | 2015-11-20 | 2017-05-26 | Effector Therapeutics, Inc. | Heterocyclic compounds that inhibit the kinase activity of mnk useful for treating various cancers |
| GB201520499D0 (en) | 2015-11-20 | 2016-01-06 | Medical Res Council Technology | Compounds |
| GB201520500D0 (en) | 2015-11-20 | 2016-01-06 | Medical Res Council Technology | Compounds |
| EP3397774A1 (en) | 2015-12-31 | 2018-11-07 | Effector Therapeutics Inc. | Mnk biomarkers and uses thereof |
| ES2955132T3 (es) * | 2016-12-19 | 2023-11-28 | Epizyme Inc | Compuestos heterocíclicos sustituidos con amina como inhibidores de EHMT2 y métodos de uso de los mismos |
| MX2019009653A (es) | 2017-02-14 | 2019-12-19 | Effector Therapeutics Inc | Inhibidores de mnk sustituidos con piperidina y metodos relacionados con los mismos. |
| US10780119B2 (en) | 2017-05-24 | 2020-09-22 | Effector Therapeutics Inc. | Methods and compositions for cellular immunotherapy |
| CA3081602A1 (en) | 2017-11-16 | 2019-05-23 | Novartis Ag | Combination therapies |
| WO2019103926A1 (en) | 2017-11-21 | 2019-05-31 | Saint Louis University | P38 inhibitors for the treatment of fshd |
| AU2019366947A1 (en) | 2018-10-24 | 2021-06-03 | Effector Therapeutics, Inc. | Crystalline forms of Mnk inhibitors |
-
2018
- 2018-02-13 MX MX2019009653A patent/MX2019009653A/es unknown
- 2018-02-13 EA EA201991894A patent/EA201991894A1/ru unknown
- 2018-02-13 JP JP2019543809A patent/JP2020507588A/ja active Pending
- 2018-02-13 DK DK18754330.1T patent/DK3582776T3/da active
- 2018-02-13 PE PE2019001676A patent/PE20191349A1/es unknown
- 2018-02-13 SG SG11201907356SA patent/SG11201907356SA/en unknown
- 2018-02-13 TW TW107105327A patent/TWI762579B/zh active
- 2018-02-13 BR BR112019016707A patent/BR112019016707A2/pt unknown
- 2018-02-13 US US15/895,523 patent/US20180228803A1/en not_active Abandoned
- 2018-02-13 FI FIEP18754330.1T patent/FI3582776T3/fi active
- 2018-02-13 WO PCT/US2018/018022 patent/WO2018152117A1/en unknown
- 2018-02-13 CA CA3053493A patent/CA3053493A1/en active Pending
- 2018-02-13 KR KR1020197026790A patent/KR20190117013A/ko not_active Application Discontinuation
- 2018-02-13 AU AU2018220840A patent/AU2018220840A1/en not_active Abandoned
- 2018-02-13 CN CN201880011685.6A patent/CN110719781A/zh active Pending
- 2018-02-13 EP EP18754330.1A patent/EP3582776B1/en active Active
- 2018-12-27 US US16/233,507 patent/US11083727B2/en active Active
-
2019
- 2019-08-09 PH PH12019550140A patent/PH12019550140A1/en unknown
- 2019-08-11 IL IL268619A patent/IL268619B/en unknown
- 2019-08-13 CL CL2019002297A patent/CL2019002297A1/es unknown
- 2019-08-29 CO CONC2019/0009423A patent/CO2019009423A2/es unknown
-
2021
- 2021-08-06 US US17/396,187 patent/US11878015B2/en active Active
-
2022
- 2022-04-29 AU AU2022202864A patent/AU2022202864A1/en active Pending
- 2022-09-29 JP JP2022156442A patent/JP2022185050A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20190275039A1 (en) | 2019-09-12 |
| EP3582776A1 (en) | 2019-12-25 |
| WO2018152117A1 (en) | 2018-08-23 |
| MX2019009653A (es) | 2019-12-19 |
| AU2018220840A1 (en) | 2019-09-19 |
| US11083727B2 (en) | 2021-08-10 |
| KR20190117013A (ko) | 2019-10-15 |
| CL2019002297A1 (es) | 2019-11-08 |
| IL268619B (en) | 2022-05-01 |
| EP3582776A4 (en) | 2020-09-02 |
| EP3582776B1 (en) | 2023-11-08 |
| AU2022202864A1 (en) | 2022-05-19 |
| BR112019016707A2 (pt) | 2020-04-07 |
| US20220096472A1 (en) | 2022-03-31 |
| US20180228803A1 (en) | 2018-08-16 |
| IL268619A (en) | 2019-10-31 |
| DK3582776T3 (da) | 2024-01-08 |
| JP2022185050A (ja) | 2022-12-13 |
| JP2020507588A (ja) | 2020-03-12 |
| FI3582776T3 (fi) | 2024-01-03 |
| CO2019009423A2 (es) | 2019-09-09 |
| CN110719781A (zh) | 2020-01-21 |
| EA201991894A1 (ru) | 2020-02-05 |
| PH12019550140A1 (en) | 2020-06-01 |
| CA3053493A1 (en) | 2018-08-23 |
| TWI762579B (zh) | 2022-05-01 |
| US11878015B2 (en) | 2024-01-23 |
| SG11201907356SA (en) | 2019-09-27 |
| TW201835076A (zh) | 2018-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20191349A1 (es) | Inhibidores de mnk sustituidos con piperidina y metodos relacionados con los mismos | |
| PE20170321A1 (es) | Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos | |
| PE20190475A1 (es) | Inhibidores de cdk2/4/6 | |
| DOP2018000187A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
| PE20120224A1 (es) | Derivados de 1h-imidazo-[4,5-c]-quinolinona | |
| AR063099A1 (es) | Compuestos y composiciones como inhibidores de la proteina quinasa | |
| AR107127A1 (es) | Indazoles sustituidos, procedimientos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos | |
| PE20130306A1 (es) | Morfolinopirimidinas y su uso en terapia | |
| PE20140250A1 (es) | Derivados de piperidina puenteada | |
| PE20151776A1 (es) | Compuestos de heteroarilo y sus usos | |
| AR106040A1 (es) | Moduladores de la proteína core de la hepatitis b | |
| PE20171307A1 (es) | Compuestos de triazolopirimidina y usos de los mismos | |
| AR088029A1 (es) | Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central | |
| PE20190811A1 (es) | Derivados de pirazolopirimidinas como inhibidor de quinasa | |
| PE20170144A1 (es) | 1h-pirrolo[2,3-c] piridin-7(6h)-onas y pirazolo[3,4-c]piridin-7(6h)-onas como inhibidores de proteinas bet | |
| AR080785A1 (es) | Derivados de imidazo[1,2-a]pirimidina ,proceso para prepararlos e intermediarios de dicha sintesis, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de patologias del sistema nervioso central,tales como esquizofrenia y parkinson, entre otros. | |
| AR104025A1 (es) | Carbamatos de piperazina como moduladores de magl y/o abhd6, procesos para su preparación y composiciones farmacéuticas | |
| PE20150218A1 (es) | Nuevos derivados fosfatos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| PE20191245A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim | |
| PE20070752A1 (es) | Triazolopiridazinas como moduladores de quinasa | |
| AR036716A1 (es) | Un compuesto derivado de bencimidazolidinona, metodos que lo utilizan, una composicion farmaceutica que lo comprende y uso de dicho compuesto o composicion | |
| PE20060185A1 (es) | ANTAGONISTA DEL RECEPTOR A2A DE LA ADENOSINA CON ESTRUCTURA DE PIRAZOLO--[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIMIDINA | |
| PE20081152A1 (es) | Azaciclilaminas n-sustituidas como antagonistas de histamina-3 | |
| AR086546A1 (es) | Derivados de 7h-purin-8(9h)-ona como inhibidores de jak | |
| AR040047A1 (es) | 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de la 5-hidroxitriptamina-6 |